TCW Group Inc. Buys 55,768 Shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC)

TCW Group Inc. lifted its stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 10.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 589,120 shares of the company’s stock after acquiring an additional 55,768 shares during the quarter. TCW Group Inc. owned 0.13% of GE HealthCare Technologies worth $46,057,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. LGT Financial Advisors LLC grew its stake in shares of GE HealthCare Technologies by 1,673.3% in the third quarter. LGT Financial Advisors LLC now owns 266 shares of the company’s stock worth $25,000 after acquiring an additional 251 shares during the period. Ashton Thomas Securities LLC purchased a new position in shares of GE HealthCare Technologies in the third quarter worth approximately $26,000. Capital Performance Advisors LLP purchased a new position in shares of GE HealthCare Technologies in the third quarter worth approximately $26,000. Darwin Wealth Management LLC purchased a new position in shares of GE HealthCare Technologies in the third quarter worth approximately $31,000. Finally, Continuum Advisory LLC boosted its holdings in shares of GE HealthCare Technologies by 101.8% in the third quarter. Continuum Advisory LLC now owns 333 shares of the company’s stock worth $31,000 after buying an additional 168 shares during the last quarter. 82.06% of the stock is currently owned by institutional investors.

GE HealthCare Technologies Price Performance

Shares of NASDAQ:GEHC opened at $91.09 on Friday. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.04 and a quick ratio of 0.83. GE HealthCare Technologies Inc. has a 1-year low of $74.51 and a 1-year high of $94.80. The company has a market capitalization of $41.66 billion, a P/E ratio of 21.04, a P/E/G ratio of 3.19 and a beta of 1.15. The firm’s 50 day simple moving average is $85.05 and its two-hundred day simple moving average is $85.86.

GE HealthCare Technologies (NASDAQ:GEHC) last released its earnings results on Thursday, February 13th. The company reported $1.45 EPS for the quarter, topping the consensus estimate of $1.26 by $0.19. GE HealthCare Technologies had a net margin of 10.13% and a return on equity of 25.74%. The firm had revenue of $5.32 billion for the quarter, compared to the consensus estimate of $5.33 billion. Research analysts expect that GE HealthCare Technologies Inc. will post 4.68 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Wells Fargo & Company raised their price objective on shares of GE HealthCare Technologies from $96.00 to $103.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Jefferies Financial Group raised shares of GE HealthCare Technologies from a “hold” rating to a “buy” rating and raised their price objective for the stock from $95.00 to $103.00 in a report on Wednesday, January 8th. Finally, Citigroup raised their price objective on shares of GE HealthCare Technologies from $103.00 to $110.00 and gave the stock a “buy” rating in a report on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $97.67.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.